NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics's Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

The most recent trading session ended with Adma Biologics (ADMA) standing at $15.62, reflecting a -1.01% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a loss of 0.18% for the day. Meanwhile, the Dow experienced a drop of 0.8%, and the technology-dominated Nasdaq saw an increase of 0.27%. Shares of the infectious disease drug developer have depreciated by 21.02% over the course of the past month, underperforming the Medical sector's loss of 3.03% and th ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

Core Points - ADMA Biologics, Inc. is under investigation for potential violations of federal securities laws following the unexpected resignation of its independent auditor, CohnReznick LLP [1] - The stock price of ADMA Biologics dropped over 20% during trading on October 10, 2024, after the announcement of the auditor's resignation [1] Company Overview - ADMA Biologics is a biopharmaceutical company that specializes in manufacturing, marketing, and developing specialty biologics aimed at treating immunodeficient patients and those at risk for infectious diseases [1] Legal Context - Bleichmar Fonti & Auld LLP, a prominent law firm known for representing plaintiffs in securities class actions, is leading the investigation into ADMA Biologics [3] - The firm has a strong track record, having recovered significant amounts from other companies, including over $900 million from Tesla's Board of Directors and $420 million from Teva Pharmaceutical Industries [3]

NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ:ADMA) on behalf of ADMA Biologics stockholders. Our investigation concerns whether ADMA Biologics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. ADMA Biologics is an end-to-end commercial bio ...

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADMA Biologics Inc (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA). Investors who purchased ADMA Biologics securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ADMA. Investigation Details On October 9, 2024, ADMA Biologics disclosed the abrupt resignation of its independe ...

ADMA Biologics, Inc.’s (ADMA) is witnessing a phenomenal run this year. Its shares have surged a whopping 262.1% in the year so far against the industry’s decline of 2.1%.The stock has been consistently touching new highs in this timeframe, having recently hit a new 52-week high of $21.13 on Oct. 9.The stock has also outperformed the sector and the S&P 500 during the aforementioned period.ADMA Outperforms Industry, Sector & S&P 500Image Source: Zacks Investment ResearchThe stupendous rally can be attributed ...